The group evaluated 1244 men and showed that combination of TMPRSS2:ERG plus PCA3 is superior in diagnosing prostate cancer having AUC of 0.751 compared to PSA plus PCA3 (AUC: 0.726) and PSA alone (AUC: 0.585) [122]. This evidence concerns the gene PCA3 and prostate cancer.